Scopolamine Market Revenue Opportunies By Key Vendors Perrigo Company plc., Caleb Pharmaceuticals, Inc., Myungmoon Pharma Co. LTD., Alchem International

The Global Scopolamine Market, by Dosage Form (Tablet, Syrup, Injection, Patch, and Others), by Distribution Channel (Hospital Pharmacies, Retail pharmacies, and Online Pharmacies) was valued US$ 370.4 million in 2017 and is projected to exhibit a CAGR of 4.8% over the forecast period (2018 - 2026) as highlighted in a new report published by Coherent Market Insights.

Scopolamine is a prescription drug used to treat muscle spasms, Parkinson’s disease, vomiting, irritable bowel syndrome, nausea, and dizziness that often accompanies motion sickness.
Download PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/1965
Although scopolamine is a completely legal drug prescribed by a physician, it has been used for illicit purposes in various economies such as UK and Colombia. Commonly scopolamine is also called as Devil’s Breath or burundanga.
The global scopolamine market size was valued at US$ 370.4 million in 2017, and is expected to witness a CAGR of 4.8% over the forecast period (2018 – 2026).

It has made headlines around the world, from Canada to Australia to Colombia, and there were at least 1,200 known cases reported in 2012 of the drug being used to force people – including politicians – into doing illegal things.
Use of scopolamine in Alzheimer's disease may prove useful as a diagnostic or staging test in the evaluation of the cholinergic system in dementia, which provides opportunities to the researchers to explore application of these drugs for other neurological disorders, which in turn is driving the market growth over the forecast period.
Manufactures in scopolamine market are focused on developing new generics through partnerships to strengthen the product portfolio. For instance, in 2017, Perrigo Company plc. and its co-development partner Aveva Drug Delivery Systems, Inc., launched scopolamine 1.5 mg transdermal system patch, generic equivalent to GlaxoSmithKline’s Transderm Scop (scopolamine 1.5 mg),

This transdermal system patch is indicated for prevention of nausea and vomiting in adults associated with motion sickness and recovery from anesthesia and/or opiate analgesia and surgery.
The annual U.S. market sales/revenue for Transderm Scop were around US$ 158 million in the 12 months ending in May 2017.

Scopolamine Market- Competitive Landscape:
Key players operating in the global scopolamine market include Baxter International Inc., GlaxoSmithKline plc. Novartis AG, Perrigo Company plc., Caleb Pharmaceuticals, Inc., Myungmoon Pharma Co. LTD., Alchem International, Phytex Australia, Centroflora-Cms, Alkaloids of Australia, and Fine Chemicals Corporation.

Request for Discount of Research Report:
https://www.coherentmarketinsights.com/insight/request-discount/1965

Key takeaways of the Scopolamine Market:
• The global scopolamine market is expected to expand at a CAGR of 4.8% during the forecast period (2018–2026), owing to high adoption of scopolamine in surgeries and post-operative recovery.
• Patches segment hold major market share among dosage forms due to utilization of these patches during surgeries to prevent hyper salivation and to speed-up the recovery from post-operative and anesthesia induced vomiting and nausea
• Major players operating in global scopolamine market include Baxter International Inc., GlaxoSmithKline plc. Novartis AG, Perrigo Company plc., Caleb Pharmaceuticals, Inc., Myungmoon Pharma Co. LTD., Alchem International, Phytex Australia, Centroflora-Cms, Alkaloids of Australia, and Fine Chemicals Corporation.

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.